Universitätsklinikum Heidelberg

AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update (2026) Hartkopf A, Albert US, Bartsch R, Bauerfeind I, Banys-Paluchowski M, Bjelic-Radisic V, Blohmer JU, et al. Journal article, Review article Comparative evaluation of disease activity measures for adult-onset Still's disease: a multicentre, retrospective, cohort study (2026) Vordenbäumen S, Filla T, Friedrich R, Blank N, Ernst D, Henes J, Keyßer G, et al. Journal article Role of Perfusion Parameters on Outcomes and Safety of Endovascular Therapy in Posterior Cerebral Artery Stroke (2026) Diel NJ, Strambo D, Abdalkader M, Qureshi MM, Dunet V, Bartolini B, Pistocchi S, et al. Journal article Evidence- and Consensus-based European Guideline for Immunosuppressive Therapy After Pediatric Kidney Transplantation (2026) Grünewald A, Ahlenstiel-Grunow T, Arslan Z, Battelino N, Rachisan ALB, Bouts A, Busutti M, et al. Journal article The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial (2026) Wies C, Messner J, Merl NB, Winterstein JT, Kommoss K, Jakob L, Fahrner HM, et al. Journal article Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis (2026) Kind B, Pham C, Heinrich L, Honstein T, Heratizadeh A, Harder I, Stölzl D, et al. Journal article Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry (2026) Traidl S, Cornelius A, Heinrich L, Siegels D, Zacharias H, Heratizadeh A, Honstein T, et al. Journal article Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (Nature Cancer, (2026), 10.1038/s43018-026-01199-y) (2026) Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, et al. Journal article, Erratum Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review (2026) Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, et al. Journal article Real-world practices and challenges of radiologically isolated syndrome: results of a cross-sector survey by the DACH MS guidelines group (2026) Held F, Bayas A, Christe K, Dettmers C, Domurath B, Ebert J, Faßhauer E, et al. Journal article